Can-Fite Biopharma Ltd (CANF) Receives Consensus Rating of “Buy” from Analysts
Can-Fite Biopharma Ltd (NASDAQ:CANF) has been given a consensus broker rating score of 2.00 (Buy) from the two analysts that provide coverage for the company, Zacks Investment Research reports. One analyst has rated the stock with a hold rating and one has issued a strong buy rating on the company.
Brokerages have set a 12 month consensus price objective of $8.00 for the company, according to Zacks. Zacks has also given Can-Fite Biopharma an industry rank of 93 out of 256 based on the ratings given to its competitors.
CANF stock traded down $0.02 during trading on Wednesday, reaching $1.19. 34,234 shares of the company traded hands, compared to its average volume of 124,400. Can-Fite Biopharma has a 12 month low of $1.00 and a 12 month high of $2.75.
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of autoimmune-inflammatory, oncological, and liver diseases, as well as sexual dysfunction. The company's lead drug candidate is CF101, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis.
Featured Article: Net Income
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Can-Fite Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Can-Fite Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.